Use Of Il-12 And Il-12 Antagonists In The Treatment Of Autoimmune Diseases

Abstract

Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-gamma or TNF-alpha. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.


Claims
Owners (US)

Information currently unavailable.

US Classifications
Download PDF
Document Preview
Document History
  • Publication: May 19, 2009
  • Application: Sep 28, 2006
    US US 52858406 A
  • Priority: Sep 28, 2006
    US US 52858406 A
  • Priority: Sep 11, 2003
    US US 65958603 A
  • Priority: Feb 25, 2000
    US US 51293000 A
  • Priority: Nov 20, 1995
    US US 56094395 A
  • Priority: Mar 14, 1994
    US US 21262994 A

Download Citation


Sign in to the Lens

Feedback